Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms

European Urology

Volumn 64, Issue 4, 2013, Pages 610-621

  Soler, Roberto ^a   Andersson, Karl Erik ^b   Chancellor, Michael B ^c   Chapple, Christopher R ^d   De Groat, William C ^e   Drake, Marcus J ^f   Gratzke, Christian ^g   Lee, Richard ^h   Cruz, Francisco ⁱ  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF PORTO   (Portugal)

Author keywords

Benign prostatic hyperplasia; Bladder; Lower urinary tract symptoms; Male; Pathophysiology; Pharmacotherapy; Prostate

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALFUZOSIN; ANTIANDROGEN; CETRORELIX; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOXAZOSIN; DUTASTERIDE; ELOCALCITOL; FINASTERIDE; GISADENAFIL; GONADORELIN; GONADORELIN ANTAGONIST; IMATINIB; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; NIFEDIPINE; NORADRENALIN; PHOSPHODIESTERASE V INHIBITOR; PROTEIN KINASE C INHIBITOR; RESINIFERATOXIN; ROFECOXIB; SILDENAFIL; SOLABEGRON; TADALAFIL; TAMSULOSIN; TENOXICAM; TOLTERODINE; UNINDEXED DRUG; VARDENAFIL;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BACTERIAL INFECTION; BLADDER CAPACITY; BLADDER DYSFUNCTION; BODY MASS; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; DRUG SAFETY; ERECTILE DYSFUNCTION; EXPERIMENTAL STUDY; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; IN VITRO STUDY; INTERNATIONAL PROSTATE SYMPTOM SCORE; LAMINA PROPRIA; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; MICTURITION; MUSCLE RELAXATION; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; TREATMENT RESPONSE; URETHRA OBSTRUCTION; URINARY FREQUENCY; UROTHELIUM;

BENIGN PROSTATIC HYPERPLASIA; BLADDER; LOWER URINARY TRACT SYMPTOMS; MALE; PATHOPHYSIOLOGY; PHARMACOTHERAPY; PROSTATE;

ANIMALS; DRUG DISCOVERY; FORECASTING; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UROLOGICAL AGENTS;

EID: 84883764805     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.04.042     Document Type: Review

References (127)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. C.R. Chapple, and C.G. Roehrborn A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder Eur Urol 49 2006 651 659
3. A. Roosen, C.R. Chapple, and R.R. Dmochowski A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature Eur Urol 56 2009 810 820
4. S.J. Berry, D.S. Coffey, P.C. Walsh, and L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479
5. C.G. Roehrborn Benign prostatic hyperplasia: an overview Rev Urol 7 Suppl 9 2005 S3 S14
6. P. Abrams Benign prostatic hyperplasia has precise meaning BMJ 322 2001 106
7. M.E. Laniado, J.L. Ockrim, A. Marronaro, A. Tubaro, and S.S. Carter Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms BJU Int 94 2004 1283 1286
8. M.D. Eckhardt, G.E. van Venrooij, and T.A. Boon Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia Urology 58 2001 966 971
9. P. Rodrigues, F. Hering, A. Meller, and M. D'Imperio Outline of 3,830 male patients referred to urodynamic evaluation for lower urinary tract symptoms: how common is infravesical outlet obstruction? Urol Int 83 2009 404 409
10. A. Cucchi, S. Quaglini, and B. Rovereto Different evolution of voiding function in underactive bladders with and without detrusor overactivity J Urol 183 2010 229 233
11. C. Chapple Systematic review of therapy for men with overactive bladder Can Urol Assoc J 5 2011 S143 S145
12. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14; discussion 1306-15.
13. C.G. Roehrborn Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Med Clin North Am 95 2011 87 100
14. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
15. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
16. S.A. Kaplan, C.G. Roehrborn, P. Abrams, C.R. Chapple, T. Bavendam, and Z. Guan Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review Int J Clin Pract 65 2011 487 507
17. K.E. Andersson, W.C. de Groat, and K.T. McVary Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action Neurourol Urodyn 30 2011 292 301
18. J.N. Cornu, P. Abrams, and C.R. Chapple A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management - a systematic review and meta-analysis Eur Urol 62 2012 877 890
19. J.D. Wilson, and C. Roehrborn Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts J Clin Endocrinol Metab 84 1999 4324 4331
20. G. Bartsch, R.S. Rittmaster, and H. Klocker Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia Eur Urol 37 2000 367 380
21. C.K. Ho, and F.K. Habib Estrogen and androgen signaling in the pathogenesis of BPH Nat Rev Urol 8 2011 29 41
22. S. Aggarwal, S. Thareja, A. Verma, T.R. Bhardwaj, and M. Kumar An overview on 5alpha-reductase inhibitors Steroids 75 2010 109 153
23. K. Shigehara, and M. Namiki Late-onset hypogonadism syndrome and lower urinary tract symptoms Korean J Urol 52 2011 657 663
24. M.D. Trifiro, J.K. Parsons, K. Palazzi-Churas, J. Bergstrom, C. Lakin, and E. Barrett-Connor Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men BJU Int 105 2009 1554 1559
25. J. Hammarsten, and R. Peeker Urological aspects of the metabolic syndrome Nat Rev Urol 8 2011 483 494
26. B.G. Timms, and L.E. Hofkamp Prostate development and growth in benign prostatic hyperplasia Differentiation 82 2011 173 183
27. K.-E. Andersson Antimuscarinic mechanisms and the overactive detrusor: an update Eur Urol 59 2011 377 386
28. E.C. Wang, J.M. Lee, and W.G. Ruiz ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells J Clin Invest 115 2005 2412 2422
29. S. Elneil, J.N. Skepper, E.J. Kidd, J.G. Williamson, and D.R. Ferguson Distribution of P2X(1) and P2X(3) receptors in the rat and human urinary bladder Pharmacology 63 2001 120 128
30. H.Y. Lee, M. Bardini, and G. Burnstock Distribution of P2X receptors in the urinary bladder and the ureter of the rat J Urol 163 2000 2002 2007
31. M. Vlaskovska, L. Kasakov, and W. Rong P2X3 knock-out mice reveal a major sensory role for urothelially released ATP J Neurosci 21 2001 5670 5677
32. K.E. Andersson Detrusor myocyte activity and afferent signaling Neurourol Urodyn 29 2010 97 106
33. K.D. McCloskey Interstitial cells of Cajal in the urinary tract Handb Exp Pharmacol 2011 2011 233 254
34. S.O. Kim, B.S. Oh, and I.Y. Chang Distribution of interstitial cells of Cajal and expression of nitric oxide synthase after experimental bladder outlet obstruction in a rat model of bladder overactivity Neurourol Urodyn 30 2011 1639 1645
35. S.M. Biers, J.M. Reynard, T. Doore, and A.F. Brading The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor BJU Int 97 2006 612 616
36. E. Inui, A. Ochiai, Y. Naya, O. Ukimura, and M. Kojima Comparative morphometric study of bladder detrusor between patients with benign prostatic hyperplasia and controls J Urol 161 1999 827 830
37. C. Fullhase, R. Soler, C. Gratzke, M. Brodsky, G.J. Christ, and K.E. Andersson Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction J Urol 184 2010 783 789
38. C. Fullhase, R. Soler, C. Gratzke, M. Brodsky, G.J. Christ, and K.E. Andersson Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction BJU Int 106 2010 287 293
39. V. Mirone, C. Imbimbo, N. Longo, and F. Fusco The detrusor muscle: an innocent victim of bladder outlet obstruction Eur Urol 51 2007 57 66
40. P.D. Metcalfe, J. Wang, and H. Jiao Bladder outlet obstruction: progression from inflammation to fibrosis BJU Int 106 2010 1686 1694
41. P. Ochodnicky, C.D. Cruz, N. Yoshimura, and M.C. Michel Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target Neurourol Urodyn 30 2011 1227 1241
42. A. Schroder, P. Chichester, and B.A. Kogan Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder J Urol 165 2001 640 646
43. M. Nomiya, D.M. Burmeister, and N. Sawada Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia J Urol 189 2013 754 761
44. G.J. Christ, and K.E. Andersson Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract Neurourol Urodyn 26 2007 948 954
45. W. Bing, S. Chang, and J.A. Hypolite Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase Am J Physiol Renal Physiol 285 2003 F990 F997
46. T.S. Kohler, and K.T. McVary The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors Eur Urol 55 2009 38 48
47. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment of non-neurogenic male LUTS. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/12-Male-LUTS.pdf. Updated 2011.
48. M. Nomiya, and O. Yamaguchi A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders J Urol 170 2003 649 653
49. K. Bouchelouche, L. Andersen, S. Alvarez, J. Nordling, and P. Bouchelouche Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin J Urol 173 2005 657 661
50. O. Ishizuka, T. Imamura, Y. Kurizaki, O. Nishizawa, and K.E. Andersson Male lower urinary tract symptoms and alpha(1) (D) -adrenoceptors Int J Urol 20 2013 73 78
51. K.E. Andersson, and A. Arner Urinary bladder contraction and relaxation: physiology and pathophysiology Physiol Rev 84 2004 935 986
52. T. Takasu, M. Ukai, and S. Sato Effect of (R)-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function J Pharmacol Exp Ther 321 2007 642 647
53. C. Fullhase, R. Soler, K. Westerling-Andersson, and K.E. Andersson Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction Neurourol Urodyn 30 2011 1382 1387
54. K.E. Andersson, C. Fullhase, and R. Soler Urothelial effects of oral agents for overactive bladder Curr Urol Rep 9 2008 459 464
55. A. Avelino, A. Charrua, and B. Frias Transient receptor potential channels in bladder function Acta Physiol (Oxf) 207 2013 110 122
56. H.T. Liu, and H.C. Kuo Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity BJU Int 100 2007 1086 1090
57. Liu L, Mansfield KJ, Kristiana I, Vaux KJ, Millard RJ, Burcher E. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodyn 2007;26:433-8; discussion 439; discussion 451-3.
58. K.E. Andersson, C. Gratzke, and P. Hedlund The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder BJU Int 106 2010 1114 1127
59. P. Consroe, R. Musty, J. Rein, W. Tillery, and R. Pertwee The perceived effects of smoked cannabis on patients with multiple sclerosis Eur Neurol 38 1997 44 48
60. C. Gratzke, T. Streng, and A. Park Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder J Urol 181 2009 1939 1948
61. V. Tyagi, B.J. Philips, and R. Su Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium J Urol 181 2009 1932 1938
62. J.S. Walczak, and F. Cervero Local activation of cannabinoid CB(1) receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents Mol Pain 7 2011 31
63. F. Strittmatter, G. Gandaglia, and F. Benigni Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats Eur Urol 61 2012 98 106
64. R.A. Harvey, D.E. Skennerton, D. Newgreen, and C.H. Fry The contractile potency of adenosine triphosphate and ecto-adenosine triphosphatase activity in guinea pig detrusor and detrusor from patients with a stable, unstable or obstructed bladder J Urol 168 2002 1235 1239
65. B.A. O'Reilly, A.H. Kosaka, T.K. Chang, A.P. Ford, R. Popert, and S.B. McMahon A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction BJU Int 87 2001 617 622
66. G. D'Agostino, A.M. Condino, V. Calvi, F. Boschi, L. Gioglio, and A. Barbieri Purinergic P2X3 heteroreceptors enhance parasympathetic motor drive in isolated porcine detrusor, a reliable model for development of P2X selective blockers for detrusor hyperactivity Pharmacol Res 65 2012 129 136
67. F. Giuliano, S. Uckert, M. Maggi, L. Birder, J. Kissel, and L. Viktrup The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia Eur Urol 63 2013 506 516
68. J.H. Guh, T.L. Hwang, F.N. Ko, S.C. Chueh, M.K. Lai, and C.M. Teng Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor Mol Pharmacol 53 1998 467 474
69. B. Fibbi, G. Penna, A. Morelli, L. Adorini, and M. Maggi Chronic inflammation in the pathogenesis of benign prostatic hyperplasia Int J Androl 33 2010 475 488
70. F. Di Silverio, V. Gentile, and A. De Matteis Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis Eur Urol 43 2003 164 175
71. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006;97(Suppl 2):7-11; discussion 21-2.
72. V. Kupelian, K.T. McVary, and M.J. Barry Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey Urology 73 2009 950 957
73. B. Chughtai, R. Lee, A. Te, and S. Kaplan Role of inflammation in benign prostatic hyperplasia Rev Urol 13 2011 147 150
74. B. Schussler Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study Urol Res 18 1990 349 352
75. O. Ishizuka, A. Mattiasson, and K.E. Andersson Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J Urol 153 1995 2034 2038
76. J.M. Park, T. Yang, L.J. Arend, A.M. Smart, J.B. Schnermann, and J.P. Briggs Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction Am J Physiol 273 1997 F538 F544
77. J.M. Park, T. Yang, and L.J. Arend Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch Am J Physiol 276 1999 F129 F136
78. J.C. Kim, E.Y. Park, S.H. Hong, S.I. Seo, Y.H. Park, and T.K. Hwang Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom Int J Urol 12 2005 875 880
79. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006;175:1773-6; discussion 1776.
80. J.K. Parsons, A.V. Sarma, K. McVary, and J.T. Wei Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions J Urol 189 2013 S102 S106
81. J.K. Parsons, H.B. Carter, and A.W. Partin Metabolic factors associated with benign prostatic hyperplasia J Clin Endocrinol Metab 91 2006 2562 2568
82. J. Hammarsten, and B. Hogstedt Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia Eur Urol 39 2001 151 158
83. H. Lepor The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia Rev Urol 8 2006 183 189
84. F. Debruyne, M. Tzvetkov, S. Altarac, and P.A. Geavlete Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia Urology 76 2010 927 933
85. NICE: medicines information. National Electronic Library for Medicines News. National Institute for Health and Care Excellence Web site. http://www.nelm.nhs.uk/en/NeLM-Area/News/2009 - -December/08/Phase-III-study- with-cetrorelix-in-benign-prostatic-hyperplasia-does-not-reach-primary-endpoint- /.
86. K. Shigehara, K. Sugimoto, and H. Konaka Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study Aging Male 14 2011 53 58
87. R.A. Appell Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination Curr Urol Rep 8 2007 370 372
88. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, and G. Barbalias Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study J Urol 169 2003 2253 2256
89. S.A. Kaplan, C.G. Roehrborn, E.S. Rovner, M. Carlsson, T. Bavendam, and Z. Guan Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328
90. K.S. Lee, M.S. Choo, and D.Y. Kim Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study J Urol 174 2005 1334 1338
91. H. Saito, T. Yamada, and H. Oshima A comparative syudy of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence Jpn J Urol Surg 12 1999 525 536
92. MacDiarmid S, Chen A, Tu N, Peters KM. Effects of tamsulosin and extended-release oxybutynin on lower urinary tract symptoms in men [abstract 1638]. Presented at: American Urological Association annual meeting; May 20-25, 2006; Atlanta, GA, USA.
93. S.A. Kaplan, W. He, W.D. Koltun, J. Cummings, T. Schneider, and A. Fakhoury Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial Eur Urol 63 2013 158 165
94. E.H. Ohlstein, A. von Keitz, and M.C. Michel A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder Eur Urol 62 2012 834 840
95. V. Khullar, J. Cambronero, and P. Stroberg The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European-Australian phase III trial Eur Urol Suppl 10 2011 278 279
96. V. Nitti, S. Rosenberg, H.D. Mitcheson, W. He, A. Fakhoury, and N. Martin Randomized, multicenter phase II study evaluating the urodynamic safety of Mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) J Urol Suppl 187 2012 756
97. J.I. Martinez-Salamanca, J. Carballido, and I. Eardley Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence Eur Urol 60 2011 527 535
98. M. Gacci, G. Corona, and M. Salvi A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 61 2012 994 1003
99. D. Altavilla, L. Minutoli, and F. Polito Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia Br J Pharmacol 167 2012 95 108
100. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005;47:72-9; discussion 78-9.
101. I. Ozdemir, O. Bozkurt, O. Demir, G. Aslan, and A.A. Esen Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms Urology 74 2009 431 435
102. P. Comeglio, A.K. Chavalmane, and B. Fibbi Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation J Endocrinol Invest 33 2010 730 738
103. L. Adorini, G. Penna, and S. Amuchastegui Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol) J Steroid Biochem Mol Biol 103 2007 689 693
104. A. Morelli, L. Vignozzi, and S. Filippi BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder Prostate 67 2007 234 247
105. L. Adorini, G. Penna, B. Fibbi, and M. Maggi Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia Ann N Y Acad Sci 1193 2010 146 152
106. A. Schroder, E. Colli, M. Maggi, and K.E. Andersson Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction BJU Int 98 2006 637 642
107. T. Streng, K.E. Andersson, and P. Hedlund Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction BJU Int 110 2012 E125 E131
108. E. Colli, P. Rigatti, and F. Montorsi BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial Eur Urol 49 2006 82 86
109. A. Tiwari Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility IDrugs 12 2009 381 393
110. G.A. Digesu, E. Verdi, L. Cardozo, L. Olivieri, V. Khullar, and E. Colli Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity Urology 80 2012 48 54
111. A. Charrua, C.D. Cruz, and S. Narayanan GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models J Urol 181 2009 379 386
112. W. Everaerts, X. Zhen, and D. Ghosh Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis Proc Natl Acad Sci U S A 107 2010 19084 19089
113. A. Charrua, C.D. Cruz, and F. Cruz TRPV1 and TRPV4 antagonists have synergistic effect for treating bladder overactivity in rats Eur Urol Suppl 11 2012 e365
114. C.M. Brady, R. DasGupta, C. Dalton, O.J. Wiseman, K.J. Berkley, and C.J. Fowler An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis Mult Scler 10 2004 425 433
115. R.M. Freeman, O. Adekanmi, M.R. Waterfield, A.E. Waterfield, D. Wright, and J. Zajicek The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS) Int Urogynecol J Pelvic Floor Dysfunct 17 2006 636 641
116. R.B. Kavia, D. De Ridder, C.S. Constantinescu, C.G. Stott, and C.J. Fowler Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis Mult Scler 16 2010 1349 1359
117. Inoue S, Saito M, Takenaka A. Hydroxyfasudil ameliorates bladder dysfunction in male spontaneously hypertensive rats. Urology 2012;79:1186 e9-14.
118. T. Masago, T. Watanabe, M. Saito, Y. Kinoshita, K. Sato, and I. Miyagawa Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model Int J Urol 16 2009 842 847
119. N. Takahashi, H. Shiomi, and N. Kushida Obstruction alters muscarinic receptor-coupled RhoA/Rho-kinase pathway in the urinary bladder of the rat Neurourol Urodyn 28 2009 257 262
120. A. Munoz, G.T. Somogyi, T.B. Boone, A.P. Ford, and C.P. Smith Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors BJU Int 110 2012 E409 E414
121. A. Schroder, M. Tajimi, H. Matsumoto, C. Schroder, M. Brands, and K.E. Andersson Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction J Urol 172 2004 1171 1174
122. N. Shore NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia Expert Opin Investig Drugs 19 2010 305 310
123. S.A. Williams, R.F. Merchant, E. Garrett-Mayer, J.T. Isaacs, J.T. Buckley, and S.R. Denmeade A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease J Natl Cancer Inst 99 2007 376 385
124. S.R. Denmeade, B. Egerdie, G. Steinhoff, R. Merchant, R. Abi-Habib, and P. Pommerville Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 59 2011 747 754
125. A. Mangera, K.E. Andersson, and A. Apostolidis Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA) Eur Urol 60 2011 784 795
126. M.B. Chancellor, C.J. Fowler, and A. Apostolidis Drug insight: biological effects of botulinum toxin A in the lower urinary tract Nat Clin Pract Urol 5 2008 319 328
127. M. Marberger, E. Chartier-Kastler, and B. Egerdie A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia Eur Urol 63 2013 496 503